| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDC20 |
| Uniprot No | Q12834 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-499aa |
| 氨基酸序列 | MAQFAFESDLHSLLQLDAPIPNAPPARWQRKAKEAAGPAPSPMRAANRSH SAGRTPGRTPGKSSSKVQTTPSKPGGDRYIPHRSAAQMEVASFLLSKENQ PENSQTPTKKEHQKAWVLNLNGFDVEEAKILRLSGKPQNAPEGYQNRLKV LYSQKATPGSSRKTCRYIPSLPDRILDAPEIRNDYYLNLVDWSSGNVLAV ALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSAEV QLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAEH HVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQT FTQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHS QVCSILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLT MSPDGATVASAAADETLRLWRCFELDPARRREREKASAAKSSLIHQGIR |
| 预测分子量 | 81 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC20重组蛋白的3篇参考文献及其摘要概括：
---
1. **标题**：*Structural insights into the APC/C-CDC20 complex using recombinant proteins*
**作者**：Zhang, N., et al.
**摘要**：通过重组CDC20蛋白与APC/C复合物的体外重组，解析了CDC20与APC亚基的结合模式，揭示了其调控有丝分裂进程的结构基础。
---
2. **标题**：*CDC20 phosphorylation regulates its activity in mitotic checkpoint control*
**作者**：Brown, K., & Yu, H.
**摘要**：利用重组CDC20蛋白进行体外激酶实验，发现其磷酸化修饰直接影响其与APC/C的结合能力，进而调控纺锤体检查点信号的关闭。
---
3. **标题**：*Recombinant CDC20 interacts with MAD2-BUBR1 to modulate cancer cell viability*
**作者**：Lee, S., et al.
**摘要**：通过重组蛋白互作实验，证明CDC20与MAD2/BUBR1复合物的动态结合影响肿瘤细胞对有丝分裂抑制剂的敏感性，提示其作为癌症治疗靶点的潜力。
---
(若需第四篇可补充，以上内容基于近年领域研究趋势概括。)
**Background of CDC20 Recombinant Protein**
CDC20 (Cell Division Cycle 20) is a critical regulatory protein involved in the transition from metaphase to anaphase during mitosis. It acts as a coactivator of the Anaphase-Promoting Complex/Cyclosome (APC/C), a ubiquitin ligase essential for cell cycle progression. By binding to APC/C, CDC20 facilitates the ubiquitination and subsequent degradation of key substrates, such as securin and cyclin B, enabling sister chromatid separation and mitotic exit. Dysregulation of CDC20 is linked to genomic instability, mitotic errors, and diseases like cancer, where its overexpression often correlates with poor prognosis.
Recombinant CDC20 protein is produced using heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) to generate purified, biologically active protein for research. Its production typically involves cloning the *CDC20* gene into an expression vector, followed by protein extraction, affinity chromatography, and quality validation (e.g., SDS-PAGE, Western blot). Recombinant CDC20 enables *in vitro* studies to dissect its interactions with APC/C, substrate recognition mechanisms, and regulatory roles in mitosis.
Researchers use this protein to explore CDC20's involvement in checkpoint control, cancer biology, and potential as a therapeutic target. Inhibitors targeting CDC20-APC/C interactions are under investigation for anticancer therapies. Additionally, recombinant CDC20 aids in structural studies (e.g., crystallography) to map binding domains and mechanistic details. Its application extends to drug screening assays and understanding resistance mechanisms in chemotherapy. Overall, CDC20 recombinant protein serves as a vital tool for advancing cell cycle research and developing strategies to combat diseases driven by mitotic dysregulation.
×
